Phaseline

Companies › Suzhou Forlong Biotechnology

Suzhou Forlong Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FL115
IL-15 agonist (IL-15[N72D]/IL-15Rα-sFc fusion protein)
IL15, IL15RAPhase 1Locally Advanced/Metastatic Solid Tumors; Advanced Solid Tumors; Non-muscle Invasive Bladder Cancer (NMIBC)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07131189FL115Phase 1Locally Advanced/Metastatic Solid TumorsOncologyJun 2026
NCT07131202FL115Phase 1Advanced Solid TumorsOncologyDec 2026
NCT07122414FL115Phase 1Non-muscle Invasive Bladder Cancer (NMIBC)OncologyOct 2027

Targets

IL15 (1) IL15RA (1)

Companies with the same targets

Beijing Biotech Innovent Biologics (Suzhou) ImmunityBio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.